Vertex Pharmaceuticals Incorporated today announced several updates on the Company's type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing ...

A Medicine study used artificial intelligence to discover a naturally occurring molecule, specifically, a peptide, that ...

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

On January 28, 2025, the Company received clearance of its IND from the FDA to initiate a first-in-human Phase 1 dose ...

Analysts at Stifel Canada issued their Q1 2025 earnings per share (EPS) estimates for Knight Therapeutics in a research note issued on Monday, March 24th. Stifel Canada analyst J. Keywood forecasts ...

Stock analysts at Stifel Canada issued their Q2 2025 earnings per share estimates for Knight Therapeutics in a research note issued on Monday, March 24th. Stifel Canada analyst J. Keywood expects that ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

As a cat enthusiast, you undoubtedly want the best for your furry companion. Cats are curious creatures, often intrigued by ...

Keywords Diabetes Mellitus, Retinopathy, Neuropathy, Nephropathy, Cardiovascular Disease Share and Cite: Mohammed, S. , ...